深圳商报记者 刘芳 在光明科学城卫光生命科学园内，中科阿尔诺生物科技有限公司的生产车间里，巨大的发酵罐正有条不 紊地运转着，透过玻璃窗望去高度自动化的设备之间由管道连通，空气中弥漫着一股淡淡的藻味，这是 细胞工厂正在"工作"的味道。 从梦想启航到创新落地 "我第一次被合成生物学的魅力折服，缘于早年的科技报道：科学家用合成生物技术成功构建细胞工厂 生产某种活性物质，100立方米工业发酵罐的产能就相当于5万亩的农业种植。用细胞工厂替代农业种 植，减少了对自然资源的依赖，大幅提高了生产效能。"这个报道坚定了陈阳致力走上合成生物技术创 新这条道路，当时她就暗暗下定决心，一定要用合成生物技术创建中国自己的"细胞工厂"。 指针拨回3年前，公司创始人、董事长陈阳第一次踏入卫光生命科学园，创新的种子在这片未启封的空 间里悄然萌芽。 如今，3300平方米的垂直工厂已成型，成为国内首个将"工业上楼"理念应用于合成生物制造的企业样 板。"这是我们自主研发的'细胞工厂'，也是光明区最大的合成生物反应器。"公司创始人、董事长陈阳 说。 从大学讲台走向产业前线 博士毕业后，陈阳当过6年大学教师，做过10年科技成果转化早期投资人，从200 ...

Core Viewpoint - The video featuring Liu Gexin, the controlling shareholder of Sichuan Kelun Pharmaceutical Co., Ltd., promoting the company's product, Ergothioneine capsules, has garnered significant attention, especially as the company faces a notable decline in profits due to the impact of centralized procurement on its infusion business [2][3]. Group 1: Company Performance - In the first quarter of this year, Kelun Pharmaceutical experienced a rare decline in both revenue and net profit, with net profit dropping over 43% year-on-year [2][11]. - The company reported a revenue of 4.39 billion yuan, a year-on-year decrease of 29.42%, and a net profit of 584 million yuan, reflecting a decline of 43.07% [11]. - Analysts attribute the decline to a high base from the previous year and the adverse effects of centralized procurement on the infusion business [11]. Group 2: Product Promotion and Market Strategy - Liu Gexin, aged 75, actively promotes the Ergothioneine capsules, showcasing his fitness and personal use of the product, which has gained over 5,100 likes on social media [3][4]. - The Ergothioneine capsules are priced at 1,499 yuan for a bottle of 60 capsules and are marketed as a cutting-edge anti-aging ingredient with superior antioxidant properties [5][6][8]. - The product is currently sold through a mini-program and is expected to expand to platforms like JD Overseas and Tmall International by late May or June [9]. Group 3: Market Potential and Industry Trends - The anti-aging market in China reached 64.6 billion yuan in 2020 and exceeded 80 billion yuan in 2021, with a growth rate of approximately 20% [12]. - Sales of Ergothioneine oral beauty products surged by 60 times on a specific e-commerce platform in the first half of 2024 [12]. - The market for health products containing Ergothioneine is rapidly growing, with numerous brands already incorporating it into their offerings [13]. Group 4: Regulatory Challenges - Currently, there are no registered or filed health products containing Ergothioneine in China, which poses a challenge for Kelun Pharmaceutical in marketing the product as a health supplement [10]. - Without proper registration or filing, the product cannot claim health benefits, as per China's Food Safety Law [10].

Core Viewpoint - 恒兴新材 is navigating a challenging market environment while focusing on growth opportunities in high-quality specialty chemicals and synthetic biology [1][2]. Group 1: Financial Performance - In 2024, 恒兴新材's overall product sales reached 65,000 tons, an increase of 30.15% year-on-year [1]. - The company's revenue surpassed 700 million yuan for the first time, marking a year-on-year growth of 13.37% [1]. - The net cash flow from operating activities was 36.3 million yuan, reflecting a year-on-year increase of 10.56% [1]. - The company's EBITDA reached 103 million yuan [1]. Group 2: Strategic Initiatives - In the first quarter of 2025, 恒兴新材 experienced significant growth in operating performance due to increased sales efforts and market expansion [2]. - The company has made strategic investments in the synthetic biology sector, partnering with 依诺基科 to leverage its technological advantages and enhance product offerings [2]. - The focus on green bio-manufacturing aims to meet market demands for environmentally friendly and health-oriented products [2]. Group 3: Agricultural Sector Focus - 恒兴新材 is committed to optimizing and upgrading its pesticide intermediates to support the performance and environmental standards of downstream agricultural producers [3]. - The company plans to explore new business models and opportunities by establishing strategic partnerships with pesticide formulation companies [3].

Investment Rating - The industry investment rating is "Overweight" [1] Core Insights - The report highlights the active research in life sciences and the global wave of biotechnology revolution, which is providing new solutions to major challenges such as health, climate change, resource security, and food security. The National Development and Reform Commission has issued the "14th Five-Year Plan for Biological Economy Development," indicating a trillion-yuan market potential in the biological economy [3][4]. Summary by Sections 1. Industry Market Dynamics - The synthetic biology sector has seen a decline of 8.90% in the recent week, ranking 32nd among various sectors [15]. - The synthetic biology index, which includes 58 companies, has underperformed compared to the Shanghai Composite Index and the ChiNext Index by 10.82% and 12.17%, respectively [4]. 2. Company Business Progress - Tianjin University has established the first synthetic biology and biomanufacturing college in China, aiming to cultivate innovative talents in response to the biotechnology revolution [7]. - Kasei Biotech and South Korea's 3P.COM have jointly established Hefei Hydrogen He New Materials Co., focusing on bio-based materials technology [8]. - The report mentions several projects and collaborations, including a biomass-based project by Luzhou Tianhua and Shanxi Coal Chemical Institute, and a partnership between Bio Island Laboratory and Wanhua Chemical [22][23]. 3. Industry Financing Tracking - The report notes an acceleration in financing for synthetic biology companies, with nearly a hundred companies completing new financing rounds since the beginning of 2025. For instance, Suzhou Yulu Qianxing Biotechnology completed several million yuan in Series A financing [27]. - Atlas Data Storage has raised $150 million in seed funding, setting a new record in the field, focusing on DNA storage technology [29].

证券代码： 000705 证券简称：浙江震元 浙江震元股份有限公司投资者关系活动记录表 编号：2025-001 | | □特定对象调研 □ 分析师会议 | | --- | --- | | □ 投资者关系活 | 媒体采访 √ 业绩说明会 | | □ 动类别 | 新闻发布会 □ 路演活动 | | □ | 现场参观 | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | 投资者网上提问 | | 时间 | 2025 年 5 月 13 日 (周二) 下午 15:00~17:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待 | 1、董事长吴海明 2、董事会秘书兼财务总监张誉锋 | | 人员姓名 | | | | 3、独立董事汪宏伟 | | | 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： | | | 1、您好，贵司 2024 年医药工业收入 6.72 亿元，其中制 | | | 剂和原料药毛利率分别为 61.25%和 20.24 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 江苏恒兴新材料科技股份有限公司（以下简称"公司"）于 2025 年 5 月 13 日（星期二）下午 13:00-14:00，通过上海证券交易所上证路演中心（网址： http://roadshow.sseinfo.com/）以网络互动方式召开了"江苏恒兴新材料科技股份有 限公司关于 2024 年度暨 2025 年第一季度业绩说明会"，就公司 2024 年度暨 2025 年第一季度经营成果、财务状况等与广大投资者进行了互动交流和沟通。 一、本次业绩说明会的召开情况 证券代码：603276 证券简称：恒兴新材 公告编号：2025-033 江苏恒兴新材料科技股份有限公司 关于 2024 年度暨 2025 年第一季度业绩说明会召开情 况的公告 公司于 2025 年 4 月 29 日通过上海证券交易所官网（http://www.sse.com.cn） 披露了《关于召开 2024 年度暨 2025 年第一季度业绩说明会的公告》 （公告编号： （ http://roadsho ...

扫码进 生物基新材料群 备注：姓名+公司+职位 资料来源： 声明： 因水平有限，错误不可避免，或有些信息非最及时，欢迎留言指出。本文由作者重新编写，仅作新材料相关领域介绍，本文 不构成任何投资建议！转载请注明来源！ 据中国化学消息，近日，由中国化学十六化建承建的微琪生物年产 3万吨合成生物PHA可降解材料项目 （一期） 通过竣工验收，标志着全国首条万吨级PHA生产线正式交付。 据悉，微琪生物是由 微构工场 与 安琪酵母 分别按照60%和40%的出资比例设立，已于2022年9月 29日完成工商注册登记，注册资本1亿元。 微琪生物3万吨PHA生物可降解材料项目是 国内拟建产能中规模最大的PHA产线 ，也是中国首条万吨 级PHA生产线 。 该项目占地约200亩，总投资10.5亿元，2023年6月正式动工，分两期建设。此次竣工的 一期 项目 总投资 2.5 亿元。 一期1万吨达产达效后，每年可实现销售额3.7亿元、税收3400万元左右。 项目采用 最前沿的生物发酵技术和先进的智能制造系统 ，规划建设集全流程自动化生产线、综合集成 信息管控平台、实时协同优化的智能生产体系、精细化能效管控于一体的绿色、安全、高效的智能工 ...

Core Viewpoint - In 2024, the company reported its first annual loss since its listing, with a net profit of -56.55 million yuan, attributed to industry adjustments, new capacity investments, and increased expenses [2][5] Financial Performance - Revenue for 2024 was 278 million yuan, a decrease of 20.92% year-on-year [2][12] - The net profit attributable to shareholders was -56.55 million yuan, marking a 309.69% decline compared to the previous year [12] - The company recorded asset impairment losses totaling 34.84 million yuan, with 27.26 million yuan related to accounts receivable [2] Business Operations - The company plans to enhance its cash flow by pursuing legal actions to expedite receivables collection, with accounts receivable amounting to 211 million yuan as of the end of Q1 [2] - The company’s main business includes the production and sale of biological feed products and inorganic solid waste treatment services [2] Strategic Initiatives - The company aims to develop synthetic biology as its third growth curve, focusing on early-stage quality projects through cautious investments [2][7] - The company has rebranded from "Lude Environmental Technology Co., Ltd." to "Lude Biological Environmental Technology Co., Ltd." to reflect its business transformation [5] Market Position and Future Outlook - The biological fermentation feed business generated 217 million yuan in revenue, accounting for 78.11% of total revenue, an increase of 31.80 percentage points from 2022 [5] - The company has expanded its production capacity from one factory to five, with a total capacity of 470,000 tons per year, and plans to increase it to 1 million tons [6][7] - The company expects stable growth in revenue and net profit for 2025, driven by the synthetic biology sector, particularly in beauty and functional food applications [7]

Core Insights - Shenzhen has introduced new legislation aimed at promoting the innovation and development of the synthetic biology industry, addressing key challenges such as supply chain coordination and long approval cycles for new materials [1][5]. Group 1: Legislative Developments - The draft regulations consist of 30 articles and aim to tackle common pain points in the synthetic biology industry, including supply chain issues and the lengthy approval process for new materials [1]. - The regulations will be open for public consultation until June 13, indicating a collaborative approach to policy-making [1]. Group 2: Market Potential - According to McKinsey, the global bioeconomy is projected to reach $2 trillion to $4 trillion in the next 10-20 years, with the contribution of biological modification expected to rise to 30%-70% over time [1][4]. - In China, 40% of newly established synthetic biology companies in the past three years are concentrated in Shenzhen, highlighting the city's growing significance in this sector [1][5]. Group 3: Industry Collaboration - The draft regulations emphasize collaboration with national and provincial health departments to enhance the safety assessment of new food materials and additives [3]. - The regulations also aim to improve the efficiency of the approval process for new cosmetic ingredients, addressing existing challenges such as high costs and long timelines [2][3]. Group 4: Support Mechanisms - Shenzhen plans to establish specialized industrial parks for synthetic biology, providing necessary R&D and production facilities, as well as public technical services [5][6]. - The city will support higher education institutions in offering programs related to synthetic biology and encourage partnerships between academia and industry to cultivate talent [5][6]. Group 5: Financial Initiatives - The Shenzhen government will leverage investment funds to support small and medium-sized enterprises in the synthetic biology sector, enhancing access to financing for startups [6]. - A private equity fund focused on synthetic biology was established in Shenzhen with a scale of 1.5 billion yuan, and local banks have increased credit limits for startups in this field [6].

Core Viewpoint - The company is focusing on a dual business strategy of "pharmaceuticals + new energy materials," with significant growth driven by the African lithium mining project and technological innovation [1][6]. Group 1: Dual Business Strategy - In Q1 2025, the company achieved a net profit of 28.11 million yuan, a substantial increase of 868.91% year-on-year, primarily due to the operational capacity release of the lithium processing plant in Nigeria and cost optimization [2]. - The lithium mining project is a key step in implementing the dual business strategy, with the first processing plant in Nigeria now operating stably, and future expansion plans will be evaluated based on market demand [2]. Group 2: Pharmaceutical Sector - The company is increasing its R&D efforts, with 13 new patents added in 2024, including 2 invention patents, and steady progress in the development of heart failure drugs [3]. - The company is also expanding into overseas markets, with a pharmaceutical company established in Tanzania and a factory in Cambodia entering production [3]. Group 3: Regulatory Impact on Pharmaceutical Excipients - The implementation of new quality management regulations for pharmaceutical excipients is expected to enhance the company's market capacity and competitiveness [4]. - The regulations emphasize the responsibility of excipient manufacturers for product quality and require stricter management and oversight processes [4]. Group 4: Technological Innovation - The company has established new technology ventures focusing on electronic components and AI applications, indicating a strategic move towards integrating technology with its core business [5]. - There is a strong emphasis on AI and intelligent technology applications in the pharmaceutical excipient manufacturing sector, with plans to build an AI innovation platform [5]. Group 5: Future Outlook - The company aims to continue strengthening its dual business strategy, enhancing technological innovation, optimizing resource allocation, and improving operational efficiency to achieve steady growth in business performance [6]. - The clear strategic planning and proactive innovation spirit position the company well for high-quality development in a complex market environment [6].